Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/9/?d=1Neue Studien: Europe PMCdeBiologics and small molecules for psoriasis: current and future progress.https://www.psoriasis-news.de/articles.html/1_articles/biologics-and-small-molecules-for-psoriasis-current-and-future-progress-r367/Weiterlesen

]]>367Sun, 30 Nov 2025 16:48:11 +0000Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Studyhttps://www.psoriasis-news.de/articles.html/1_articles/patient-experiences-on-the-diagnosis-management-and-burden-of-generalized-pustular-psoriasis-an-international-web-survey-and-qualitative-interview-study-r366/No abstract supplied.

Weiterlesen

]]>366Sun, 30 Nov 2025 16:48:11 +0000Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.https://www.psoriasis-news.de/articles.html/1_articles/consensus-definitions-of-complex-to-manage-and-treatment-refractory-psoriatic-arthritis-a-grappa-initiative-r365/Weiterlesen

]]>365Sun, 30 Nov 2025 16:48:11 +0000Psoriasis treatment training in dermatology residency: a Latin American survey of faculty and residents.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-treatment-training-in-dermatology-residency-a-latin-american-survey-of-faculty-and-residents-r364/ObjectiveThis study evaluated psoriasis treatment teaching in dermatology residency programs across Latin America (LATAM).

Methods

A Spanish/Portuguese survey was distributed to directors of dermatology departments/training programs and their residents in several LATAM countries between November 29, 2022, and March 31, 2023.

Results

A total of 108 individuals responded (59 directors and 49 residents) from eight countries: Argentina (2.8%), Brazil (41.7%), Chile (25.0%), Colombia (7.4%), Guatemala (1.9%), Mexico (1.9%), Paraguay (4.6%), and Peru (14.8%). Most directors reported that residents received training in complex medical dermatology (89.8%), immunodermatology (66.1%), and phototherapy (78%). Most residents reported familiarity with national guidelines (81.6%) and adherence to local guidelines (85.7%). In Brazil, 91% of programs had at least seven faculty members, 97% required national specialization exams, and 91% treated more than 31 psoriasis patients per week, compared with 48%, 36%, and 67% in other LATAM countries, respectively. Additionally, 47% of centers in Brazil reported that at least 26% of psoriasis patients received biological therapy, compared with only 8% in other LATAM countries.

Conclusion

Dermatology residents in LATAM are trained in complex dermatology, immunodermatology, and phototherapy and national psoriasis guidelines. Variation exists in patient volume and biologics use. A focus on improving residents' psoriasis training throughout LATAM is needed.

Weiterlesen

]]>364Sun, 30 Nov 2025 16:48:11 +0000Screening of key genes related to disulfidptosis in psoriasis based on the analysis of WGCNA.https://www.psoriasis-news.de/articles.html/1_articles/screening-of-key-genes-related-to-disulfidptosis-in-psoriasis-based-on-the-analysis-of-wgcna-r363/Weiterlesen

]]>363Sun, 30 Nov 2025 16:48:11 +0000Dysbiosis of the Saliva Microbiota in Patients with Psoriasis: A Case-Control Study.https://www.psoriasis-news.de/articles.html/1_articles/dysbiosis-of-the-saliva-microbiota-in-patients-with-psoriasis-a-case-control-study-r362/PurposeAccumulating evidence supports the association between altered salivary microbiota and inflammatory diseases. The existing literature on the salivary microbiota in patients with psoriasis is limited. However, differences in the prevalence of Candida species and abundance of several bacterial taxa in saliva have been found between patients and controls. This study aimed to investigate the differences in the composition and functional potential of salivary microbiota in patients with psoriasis compared to their cohabiting partners and healthy controls.

Patients and methods

Samples from 115 of 123 individuals qualified for statistical analysis: patients with psoriasis who did not receive systemic anti-psoriatic treatment (n=47); cohabiting partners (n=21); and age-, sex-, and BMI-matched healthy controls (n=47). One saliva sample was collected from each participant and analysed by shotgun metagenomic sequencing.

Results

A difference in the α-diversity of bacterial species was observed exclusively between patients and controls, with a lower diversity in patients (p=0.041). Variation in bacterial composition (β-diversity) was influenced by smoking (p=0.001) and diet (p=0.025) but not by group status. Using a linear regression model adjusted for smoking and diet, we identified four bacterial classes and five species that were significantly different between the patient, partner, and control groups. One Kyoto Encyclopedia of Genes and Genomes module differed significantly between patients with psoriasis and their partners. No differences in Candida species or abundance were found among the three groups.

Conclusion

Comparison of salivary microbiota at the levels of bacterial diversity, composition, and predicted function indicated that psoriasis cases are characterised by dysbiosis.

Weiterlesen

]]>362Sun, 30 Nov 2025 16:48:11 +0000TNF-α-Driven Systemic Inflammasome Hyperactivity Links Psoriatic Inflammation to monocyte inflammatory response and platelet activationhttps://www.psoriasis-news.de/articles.html/1_articles/tnf-%CE%B1-driven-systemic-inflammasome-hyperactivity-links-psoriatic-inflammation-to-monocyte-inflammatory-response-and-platelet-activation-r361/ABSTRACT

Background

Psoriasis is a chronic skin disease mediated by Th1 and Th17 immune responses and is classified as a systemic inflammatory disorder. Notably, psoriasis is an independent risk factor for myocardial infarction, stroke, and cardiovascular mortality, particularly in severe disease. However, the cellular mechanisms linking psoriasis to cardiovascular disease risk have not yet been identified. To address this gap, we investigated systemic markers of inflammasome signaling and innate immune activation in patients with psoriasis.

Methods

Whole blood was collected from 43 patients, including active psoriasis (mild-to-moderate disease) without clinical manifestations of atherosclerosis, inactive psoriasis (minimal disease activity), patients receiving anti-TNF-α therapy, and 19 BMI-matched healthy controls. Multiparametric spectral flow cytometry was performed to profile inflammasome signaling, and mass spectrometry-based proteomics was used to obtain unbiased phenotyping of circulating immune cells.

Results

Classical monocytes from patients with active psoriasis exhibited heightened NLRP3 protein expression and caspase-1 activity upon brief physiological stimulation, responses absent in inactive psoriasis and healthy controls. Mechanistically, active psoriasis demonstrated elevated plasma ATP and increased monocyte expression of P2X7R, a potent NLRP3 activator. TNF-α was identified as a key cytokine, selectively upregulating both P2X7R and NLRP3. Baseline proteomics revealed enriched pathways for monocyte extravasation and cell adhesion, suggesting a pro-thrombotic state. Stimulation increased proteins linked to ROS and mitochondrial stress. Monocytes from active psoriasis exhibited increased baseline activation and, upon stimulation, enhanced monocyte-platelet aggregation, both of which were attenuated by inhibition of mitochondrial ROS. Importantly, anti-TNF therapy normalized ATP levels, P2X7R expression, inflammasome responsiveness, monocyte activation, and monocyte-platelet interactions, supporting the restoration of systemic immune homeostasis.

Conclusions

In patients with mild-to-moderate psoriasis, we demonstrate persistent systemic stress, resulting in inflammasome hyperreactivity and increased monocyte-platelet aggregation in response to minor perturbations in cellular homeostasis. Notably, TNF-α blockade restores these effects, providing mechanistic insight into how anti-TNF therapy reduces systemic inflammation and cardiovascular risk.

What is already known about this topic?

Psoriasis is a systemic, immune-mediated skin disease that is associated with an increased risk of cardiovascular disease (CVD), particularly in severe disease. The NLRP3 inflammasome, an innate immune sensor, has been implicated in the pathogenesis of CVD. Anti-TNF therapy, which is effective in treating psoriasis, is proposed to reduce CVD risk, but the underlying mechanisms remain unclear.

What does this study add?

Patients with mild-to-moderate psoriasis without clinical manifestations of atherosclerosis demonstrate elevated plasma ATP levels, increased monocyte P2X7 receptor expression, and enriched pathways for monocyte activation and extravasation, suggesting persistent systemic stress. Monocytes from these patients display ROS-dependent hyperactivation of the NLRP3 inflammasome and increased formation of monocyte-platelet aggregates in response to minor perturbations in cellular homeostasis. TNF-α was identified as a key cytokine, selectively upregulating both P2X7R and NLRP3. Anti-TNF therapy normalized these aberrant immune responses, suggesting a mechanism for its proposed cardioprotective effects.

Novelty and significance

This study provides evidence that patients with mild to moderate psoriasis, without clinical manifestations of atherosclerosis, exhibit concurrent elevations in plasma ATP levels, monocyte P2X7 receptor expression, inflammasome responsiveness, and monocyte-platelet aggregates: features increasingly associated with CVD risk. These findings suggest that dysregulated purinergic signaling may contribute to systemic immune activation in psoriasis. Importantly, anti-TNF therapy was associated with normalization of these parameters, pointing toward a potential immunomodulatory mechanism by which such treatment may help reduce CVD risk. These observations highlight a novel intersection between inflammation, purinergic signaling, and monocyte-platelet activation, which may contribute to the increased CVD risk in psoriasis.

Weiterlesen

]]>361Sun, 30 Nov 2025 16:48:11 +0000Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-adalimumab-treatment-on-impairment-of-non-professional-activities-in-psoriasis-patients-r360/Background and objectivesPsoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non-professional activities. This study investigates the effects of long-term treatment with adalimumab regarding work ability, non-professional activities, and health-related quality of life in a large real-word population in Germany.

Patients and methods

Single-arm, multicenter non-interventional study to document routine care data for up to 5 years in adult patients with psoriasis after initiation of adalimumab.

Results

Baseline data was collected for 4,793 (62.1 % male) patients with a mean (± SD) age of 47.5 ± 13.11 years. The number of days with restrictions in non-professional activities was much higher than in professional activities. Under adalimumab, the psoriasis-related number of days unfit for work and number of days with restrictions in non-professional activities significantly decreased. Correlation analyses showed that psoriatic arthritis, disease severity (PASI > 10), and impairment of quality of life (DLQI > 10) are associated with restrictions in non-professional activities. Health-related quality of life improved over the observed time but remained reduced in patients with restrictions in non-professional activities.

Conclusions

Long-term treatment with adalimumab had a favorable impact on clinical outcomes, employment-related aspects, practice of non-professional activities, and health-related quality of life in psoriasis patients.

Weiterlesen

]]>360Sun, 30 Nov 2025 16:48:11 +0000Psychiatric evaluation and personality in psoriasis patients.https://www.psoriasis-news.de/articles.html/1_articles/psychiatric-evaluation-and-personality-in-psoriasis-patients-r359/Weiterlesen

]]>359Sun, 30 Nov 2025 16:48:11 +0000Anterior Extrusion of an Orthobiologic Sacroiliac Joint Implant in a Patient With Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/anterior-extrusion-of-an-orthobiologic-sacroiliac-joint-implant-in-a-patient-with-psoriatic-arthritis-r358/BackgroundSacroiliac joint (SIJ) pain accounts for a large portion of low back pain within the population. Management for this SIJ pain consists of many non-invasive treatments including physical therapy, nerve ablation, intra-articular SIJ injections, bracing, and manipulative therapy. Pain that proves to be resistant to these modalities has previously been considered for surgical stabilization through a transiliac approach, which involves placement of screws.

Aims

To describe the anterior extrusion of a SIJ implant following arthrodesis, which is a unique complication of a minimally invasive SIJ fusion via the posterior approach.

Materials and methods

A 52 year old female with a past medical history of psoriatic arthritis and alanto-axial instability presented with a year-long history of bilateral lower back and right-sided posterior thigh and buttock pain. Evaluation included lumbar MRI and pelvic CT. Based on these findings, she underwent minimally invasive posterior SIJ fusion using the LinQ allograft. Her symptoms and response to treatment were documented throughout her clinic follow-ups.

Results

Imaging revealed degenerative SIJ changes. She subsequently underwent several rounds of SIJ steroid injections. Due to continued pain, she opted to have a minimally invasive SIJ fusion via the posterior approach, first on the right side and then on the left side. After several months of persistent, reaggravated SIJ pain, a repeat pelvic CT showed anterior extrusion of the right SIJ allograft.

Discussion

More recently, multiple minimally invasive techniques for SIJ fusions have been developed, one of them being posterior insertion of an orthobiologic implant. Minimally invasive SIJ fusion has been shown to provide pain relief and decrease disability. Posterior implant insertion to partially fuse the SIJ carries minimal risk of complications, one of which is posterior dislodgment of the implant. However, anterior extrusion of the implant has not, to our knowledge, been described or reported.

Weiterlesen

]]>358Sun, 30 Nov 2025 16:48:11 +0000Psoriatic Arthritis: From Diagnosis to Treatment.https://www.psoriasis-news.de/articles.html/1_articles/psoriatic-arthritis-from-diagnosis-to-treatment-r357/Weiterlesen

]]>357Fri, 28 Nov 2025 18:56:31 +0000Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study.https://www.psoriasis-news.de/articles.html/1_articles/real-world-evidence-for-repurposing-hydralazine-as-a-potential-epigenetic-modulator-for-psoriasis-a-16-year-retrospective-nationwide-cohort-study-r356/No abstract supplied.

Weiterlesen

]]>356Fri, 28 Nov 2025 18:56:31 +0000Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors.https://www.psoriasis-news.de/articles.html/1_articles/joint-position-statement-from-the-national-psoriasis-foundation-medical-board-and-the-international-psoriasis-council-on-routine-testing-for-latent-tuberculosis-infection-prior-to-and-during-treatment-of-psoriasis-patients-with-il-17-or-il-23-inhibitors-r355/BackgroundAlthough testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with IL-17 or IL-23 inhibitors, evidence for this practice is weak.

Objectives

To review evidence on safety of IL-17 and IL-23 inhibitors in the setting of latent TB infection, and to provide a new Joint Position Statement on this topic.

Methods

Experts from the National Psoriasis Foundation (NPF) and the International Psoriasis Council (IPC) reviewed evidence regarding progression of latent TB infection to active disease in psoriasis patients receiving IL-17 or IL-23 blockers. A Joint Position Statement was formulated and approved to provide updated guidance to clinicians.

Results

87.5% of the members from the NPF Medical Board and IPC approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required.

Limitations

This position statement allows for exceptions where continued testing for latent TB infection could be considered, including for patients on concomitant immunosuppressive therapy and for those living in TB endemic areas.

Conclusion

Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.

Weiterlesen

]]>355Fri, 28 Nov 2025 18:56:31 +0000Switching from Intravenous to Subcutaneous Infliximab Maintains Efficacy and Enhances Treatment Satisfaction in Patients with Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/switching-from-intravenous-to-subcutaneous-infliximab-maintains-efficacy-and-enhances-treatment-satisfaction-in-patients-with-psoriasis-r354/Background: /Objectives: Plaque psoriasis is a chronic immune-mediated inflammatory disease affecting approximately 3% of the global population and resulting in a significant deterioration in quality of life. Systemic therapy with monoclonal antibodies (mAbs) targeting TNF-α, IL-23, and IL-17 improves clinical outcomes and patients’ quality of life. Treatment strategies commonly include different mAbs and different sequencings approaches between agents, which are well-established in clinical practice. In contrast, evidence supporting the switch from intravenous to subcutaneous administration of the same mAb remains limited. Herein, we report data from a retrospective case series of patients with plaque psoriasis treated with intravenous infliximab (IV-IFX; Anti TNF-α) and transitioned to subcutaneous infliximab (SC-IFX) to compare clinical and patient-reported outcomes across routes.

Methods:

11 plaque psoriasis patients were retrospectively analyzed. The scores of Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and Physician Global Assessment (PGA) were assessed during IV-IFX and after switching to SC-IFX. To evaluate patients’ satisfaction, the Score of Treatment Satisfaction Questionnaire Medication-9 (TSQM-9) was evaluated. Both Student’s t-test and ANOVA were used to assess statistically significant differences between the two routes of administration (p<0.05).

Results:

scores for PASI, DLQI and PGA were lower with SC-IFX compared to IV-IFX, indicating improved disease control and quality of life after the switch. PASI and DLQI improved in 81% and 100% of patients treated with SC-IFX, respectively. TSQM-9 total scores increased significantly by 24% (P<0.001). In particular, the questions addressing the “convenience” of treatment, revealed a marked advantage for the SC-IFX formulation (p<0.001). No treatment-emergent adverse events were registered.

Conclusions:

In this retrospective case series, switching from IV-IFX to SC-IFX appeared to be safe and to maintain or improve clinical response and enhanced treatment satisfaction. Thus, these findings highlight the potential of SC-IFX as a viable maintenance option for patients with plaque psoriasis previously treated with IV-IFX.

Weiterlesen

]]>354Fri, 28 Nov 2025 18:56:31 +0000Burden of immune-related skin diseases worldwide, 1991–2021: insights and prediction from the Global Burden of Disease Studyhttps://www.psoriasis-news.de/articles.html/1_articles/burden-of-immune-related-skin-diseases-worldwide-19912021-insights-and-prediction-from-the-global-burden-of-disease-study-r353/No abstract supplied.

Weiterlesen

]]>353Fri, 28 Nov 2025 18:56:31 +0000TNF-α-Driven Systemic Inflammasome Hyperactivity Links Psoriatic Inflammation to monocyte inflammatory response and platelet activationhttps://www.psoriasis-news.de/articles.html/1_articles/tnf-%CE%B1-driven-systemic-inflammasome-hyperactivity-links-psoriatic-inflammation-to-monocyte-inflammatory-response-and-platelet-activation-r352/Weiterlesen

]]>352Fri, 28 Nov 2025 18:56:31 +0000Sternoclavicular joint involvement in psoriatic arthritis: a hidden indicator of disease severity.https://www.psoriasis-news.de/articles.html/1_articles/sternoclavicular-joint-involvement-in-psoriatic-arthritis-a-hidden-indicator-of-disease-severity-r351/ObjectivesSternoclavicular joint (SCJ) involvement in psoriatic arthritis (PsA) is poorly characterized. We aimed to assess its prevalence and clinical associations in a longitudinal PsA cohort.

Methods

We retrospectively analyzed prospectively collected data from the Gladman Krembil Psoriatic Arthritis Program. Patients with SCJ involvement (tender and/or swollen SCJ) were identified, and their demographic, clinical, laboratory, and treatment details were retrieved. Univariable and multivariable generalized estimating equation models were used to assess associations with clinically swollen SCJ. Results are reported as odds ratios (OR) with 95% confidence intervals (CI).

Results

Among 1,737 patients, 182 (10.5%) had SCJ involvement, including 36 (2.1%) with clinically swollen SCJs ever over follow-up. SCJ involvement was present at enrolment into the cohort (baseline) in 33.1% of affected individuals. The mean age was 41.4 ± 12 years, and 42% were male. In univariable analyses, SCJ involvement was significantly associated with higher swollen joint count (SJC) (OR 1.142, 95% CI 1.08-1.16), dactylitis (4.51, 2.02-10.05), and enthesitis (6.74, 3.45-13.15). No significant associations were observed with sex, disease duration, axial and nail disease, PASI, pustular psoriasis, or HLA markers. In multivariable analysis, SCJ swelling remained associated with higher SJC (1.08, 1.03-1.14), enthesitis (4.54, 1.98-10.45), dactylitis (4.54, 1.98-10.45) and lower biologic or targeted synthetic DMARD use (0.30, 0.10-0.88).

Conclusion

SCJ involvement is an underrecognized but clinically meaningful manifestation of PsA, associated with greater disease burden and enthesitis, often requiring escalation to advanced therapies.

Weiterlesen

]]>351Fri, 28 Nov 2025 18:56:31 +0000Comparing the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin for psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/comparing-the-effectiveness-and-drug-persistence-of-methotrexate-cyclosporine-and-acitretin-for-psoriasis-r350/BackgroundConventional systemic agents remain the cornerstone treatment for psoriasis because of their availability and cost-effectiveness. However, few studies have compared the effectiveness and drug persistence of these agents in Asian populations.

Objectives

To evaluate the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin, and to identify factors associated with these outcomes.

Methods

We reviewed data from 338 psoriasis patients treated with methotrexate, cyclosporine, or acitretin.

Results

Out of 473 treatment courses, 239 (50.5%) involved methotrexate, 123 (26%) involved acitretin, and 111 (23.5%) involved cyclosporine. After 1 year, the proportion of patients who achieved absolute Psoriasis Area and Severity Index (PASI) ≤ 2 was greater with methotrexate (30.6%) and cyclosporine (22.2%) than with acitretin (9.5%). For absolute PASI ≤ 4, methotrexate (57%) and cyclosporine (47.2%) showed greater effectiveness than did acitretin (34.9%), with a significant difference only between methotrexate and acitretin (P = .017). The effectiveness findings were consistent in both the 1- and 3-year analyses. Multivariate analysis revealed that a high baseline PASI score significantly reduced the effectiveness of both methotrexate and cyclosporine. For methotrexate, a high body mass index was also associated with reduced effectiveness, whereas for acitretin, scalp involvement and male sex were key factors. Methotrexate demonstrated the longest drug survival at 1 year. Higher ages at psoriasis onset and systemic treatment-naive status were correlated with longer drug survival. Conversely, a higher body mass index and psychiatric comorbidities were linked to shorter survival.

Limitations

Methotrexate is typically the first-line systemic therapy in Thailand, which may underestimate the true efficacy of cyclosporine and acitretin when used subsequently.

Conclusion

Methotrexate was more effective and persistent than were cyclosporine and acitretin in a real-world setting.

Weiterlesen

]]>350Fri, 28 Nov 2025 18:56:31 +0000Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world study.https://www.psoriasis-news.de/articles.html/1_articles/reduction-of-impairment-of-sexual-activity-in-patients-with-genital-psoriasis-treated-with-risankizumab-interim-results-of-a-real-world-study-r349/p < 0.001). In the GPSIS avoidance and impact subscale, more patients reported 'never' avoiding sexual activity at week 16 compared to baseline (46.8% vs. 10.5%) and 78.9% reported 'no or very low' impact compared to 18.5% at baseline, respectively. These findings indicate risankizumab significantly reduces patient-reported GenPsO symptoms over a 16-week period and increases sexual QoL.

Weiterlesen

]]>349Fri, 28 Nov 2025 18:56:31 +0000Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature reviewhttps://www.psoriasis-news.de/articles.html/1_articles/temporarily-induced-facial-eczema-by-il-17-inhibitors-a-case-report-and-literature-review-r348/No abstract supplied.

Weiterlesen

]]>348Fri, 28 Nov 2025 18:56:31 +0000The pivotal role of Interleukin-23 in the skin-gut-joint axis.https://www.psoriasis-news.de/articles.html/1_articles/the-pivotal-role-of-interleukin-23-in-the-skin-gut-joint-axis-r346/Weiterlesen

]]>346Tue, 25 Nov 2025 19:50:44 +0000Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysishttps://www.psoriasis-news.de/articles.html/1_articles/clinical-benefits-and-complication-profile-of-il-23-inhibitors-in-patients-with-psoriatic-arthritis-a-systematic-review-and-meta-analysis-r345/No abstract supplied.

Weiterlesen

]]>345Tue, 25 Nov 2025 19:50:44 +0000Exploring the mechanism of Notopterygii rhizoma et radix in the treatment of psoriasis using a network Pharmacology approach and experimental validation.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-mechanism-of-notopterygii-rhizoma-et-radix-in-the-treatment-of-psoriasis-using-a-network-pharmacology-approach-and-experimental-validation-r344/Weiterlesen

]]>344Tue, 25 Nov 2025 19:50:44 +0000Coronary Artery Disease Assessment in Psoriasis Patients Well-Controlled Under Systemic Anti-Inflammatory Treatments-A Real-World Observational Study From a Single Center.https://www.psoriasis-news.de/articles.html/1_articles/coronary-artery-disease-assessment-in-psoriasis-patients-well-controlled-under-systemic-anti-inflammatory-treatments-a-real-world-observational-study-from-a-single-center-r343/Weiterlesen

]]>343Tue, 25 Nov 2025 19:50:44 +0000TGM1 as a novel signature gene in psoriasis identified by integrative bioinformatics and experimental validation.https://www.psoriasis-news.de/articles.html/1_articles/tgm1-as-a-novel-signature-gene-in-psoriasis-identified-by-integrative-bioinformatics-and-experimental-validation-r342/Weiterlesen

]]>342Tue, 25 Nov 2025 19:50:44 +0000